These findings are consistent with those observed in our nested cohort of outpatients with COVID-19 treated with PTIC, where there was a decreased serum IP-10, IL-8, eotaxin, and M-CSF, all early markers of Mo1 associated with severe diseases [36,37,38,39,40]. This evidence concerns the gene CCL11 and COVID-19.